Skip to content
OpenCapital
Get started

Repligen RGEN EBIT

EBIT at other companies

TEC
Bio-TechneTECH
——
Revvity logo
RevvityRVTY
——
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
——
Danaher logo
DanaherDHR
——
Agilent Technologies logo
Agilent TechnologiesA
——
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
——

Other financials

Income statement

See full
Revenue$194.3M+14.8%
Gross profit$108.3M+18.5%
Operating income$15.9M+142%
Net income$8.3M+42.9%
EPS (diluted)$0.15+50.0%

Balance sheet

See full
Cash & equivalents$582.7M-16.4%
Total debt$687.6M+346%
Total equity$2.1B+6.0%
Total assets$2.9B+2.8%

Cash flow

See full
Operating cash flow$28.3M+88.6%
CapEx$4.7M+32.2%
Free cash flow$23.6M+106%

Valuation

See full
Market cap$7.45B-7.1%
Enterprise value$7.55B+2.1%
P/E144.9×—
P/S10.1×-0.1×

Profitability

See full
Gross margin49.5%+2.7pp
Operating margin1.5%-14.0pp
Net margin17.1%-3.7pp
FCF margin21.2%+6.1pp

Returns & leverage

See full
Return on equity2.5%+1.9pp
Debt / equity0.3×+0.2×
Current ratio9.2×+2.4×

Where this comes from

Calculated from Repligen’s reported figures.

$15.9Moperating income+$1.8Mincome before tax+$5.6Minterest expense=$15.94M

The official record: Repligen’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Repligen's ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Repligen's EBIT?
Repligen (RGEN) reported EBIT of $15.94M in Q1 2026.
How has Repligen's EBIT changed year-over-year?
Repligen's EBIT increased by 142.3% year-over-year, from $6.58M to $15.94M.
What is the long-term trend for Repligen's EBIT?
Over 2 years (2021 to 2023), Repligen's EBIT has grown at a -37.6% compound annual growth rate (CAGR), from $167.25M to $65.22M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.